Intercept Pharmaceuticals Inc (ICPT) 209.12 $ICPT
Intercept Pharmaceuticals concludes public offering of 1m common shares and exercise of underwriters' full option
M2 - Wed Feb 11, 5:13AM CST
Biopharmaceutical company Intercept Pharmaceuticals (NasdaqGS:ICPT) said on Tuesday that it has completed the public offering of 1,000,000 shares of its common stock.
ICPT: 209.12 (+7.12)
Intercept Pharma completes equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:22PM CST
ICPT: 209.12 (+7.12)
Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
GlobeNewswire - Tue Feb 10, 3:08PM CST
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced the completion of its previously announced underwritten public offering of 1,000,000 shares of its common stock. In addition, the underwriters have exercised in full their option to purchase an additional 150,000 shares of common stock.
ICPT: 209.12 (+7.12)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
Does This Small Biotech Have the Making of a Blockbuster?
Motley Fool Staff - Motley Fool - Sat Feb 07, 8:59AM CST
Source: Flickr user Stockmonkeys.com. When it comes to developing billion-dollar blockbuster drugs, the odds are stacked against biotech companies. About 90% of drugs that enter clinical trials fail, and of those that do eventually get approved,...
OPHT: 51.11 (+0.12), ICPT: 209.12 (+7.12), ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Intercept Pharmaceuticals (ICPT) Jumps: Stock Adds 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:25AM CST
Intercept Pharmaceuticals (ICPT) was a big mover last session, with shares rising roughly 10% on the day.
ICPT: 209.12 (+7.12), AFFX: 11.45 (+0.02)
Why Intercept Pharmaceuticals Inc. Shares Shot Higher By 29% in January
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 05, 10:04AM CST
ICPT data by YCharts What: Shares of Intercept Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat liver and intestinal diseases, shot higher by 29% in January per S&P Capital IQ after...
ICPT: 209.12 (+7.12)
Intercept Pharmaceuticals prices public offering at USD176.00 per share
M2 - Thu Feb 05, 5:45AM CST
Biopharmaceutical company Intercept Pharmaceuticals (NasdaqGS:ICPT) said on Wednesday that it has priced its public offering of 1,000,000 shares of its common stock at USD176.00 per share.
ICPT: 209.12 (+7.12)
Intercept Pharmaceuticals Announces Pricing of Public Offering
GlobeNewswire - Wed Feb 04, 6:34PM CST
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $176.00 per share. In addition, Intercept has granted the underwriters a 30-day option to purchase up to an additional 150,000 shares of common stock.
ICPT: 209.12 (+7.12)
Intercept Pharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 9:04PM CST
ICPT: 209.12 (+7.12)
Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Feb 03, 3:18PM CST
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced that it has commenced an underwritten public offering of 800,000 shares of its common stock. All of the shares in the offering are to be sold by Intercept.
ICPT: 209.12 (+7.12)
Intercept Pharmaceuticals (ICPT) Marked As A Dead Cat Bounce Stock
at The Street - Tue Feb 03, 1:17PM CST
Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a "dead cat bounce" (down big yesterday but up big today) candidate
ICPT: 209.12 (+7.12)
Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 03, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ARLP: 39.29 (+1.84), HTBX: 5.83 (+0.22), EVOK: 5.41 (-0.10), ADXS: 7.18 (+0.06), RCII: 30.49 (+0.92), SCYX: 9.48 (+0.07), SONS: 17.69 (-0.01), SSYS: 67.16 (-0.34), ICPT: 209.12 (+7.12), VBLT: 14.11 (+0.24), LMNX: 15.45 (+0.02), OMER: 20.63 (+0.13)
Critical Alerts For Zynga, Intercept Pharmaceuticals, Biogen, Nabors Industries and CyberArk Software Released By InvestorsObserver
PR Newswire - Mon Feb 02, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ZNGA, ICPT, BIIB, NBR and CYBR.
BIIB: 391.66 (-0.45), CYBR: 52.52 (+6.83), NBR: 12.73 (+0.52), ICPT: 209.12 (+7.12), ZNGA: 2.24 (-0.42)
Quarterly Results Review & Outlook: Complementary Reports on Costco, Chevron, ImmunoGen, MasterCard, and Intercept
PR Newswire - Mon Feb 02, 6:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Costco (NASDAQ: COST), Chevron (NYSE: CVX), ImmunoGen (NASDAQ: IMGN), MasterCard (NYSE: MA), and Intercept (NASDAQ: ICPT). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
IMGN: 7.19 (unch), ICPT: 209.12 (+7.12), COST: 147.10 (-0.66), CVX: 112.78 (+1.92), MA: 87.14 (-0.38)
Intercept Pharmaceuticals wins US FDA's "breakthrough therapy designation" for investigational product obeticholic acid for NASH with liver fibrosis
M2 - Mon Feb 02, 5:20AM CST
Biopharmaceutical company Intercept Pharmaceuticals (NasdaqGS:ICPT) revealed on Friday that it has received "breakthrough therapy designation" for its investigational product obeticholic acid (OCA) from the US Food and Drug Administration (FDA) for treating patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis.
ICPT: 209.12 (+7.12)
Intercept Pharmaceuticals' OCA Now Breakthrough Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 3:54PM CST
Intercept Pharmaceuticals, Inc.'s (ICPT) obeticholic acid (OCA) received Breakthrough Therapy designation from the FDA for nonalcoholic steatohepatitis (NASH).
MNK: 115.01 (+2.51), ICPT: 209.12 (+7.12), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Primary Sclerosing Cholangitis Therapeutic Pipeline Review H1 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Fri Jan 30, 3:30PM CST
The report "Primary Sclerosing Cholangitis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Primary Sclerosing Cholangitis. Primary sclerosing cholangitis is a liver disease in which the bile ducts gradually decrease in size due to swelling and scarring. Different treatments are available to control symptoms that may develop and also to manage any complications which may occur. Many people with primary sclerosing cholangitis do not get symptoms, especially in the early stages of the disease. The most common symptoms are fatigue, pruritus, jaundice and yellowing of the skin and eyes. The symptoms of this disease can be treated with antibiotics, vitamins and medications to control itching, improve bile flow etc. Complete Report is Available at http://www.rnrmarketresearch.com/primary-scle...eport.html.
GILD: 101.90 (+1.10), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
Intercept Pharmaceuticals concludes public offering of 1m common shares and exercise of underwriters' full option
M2 - Wed Feb 11, 5:13AM CST
Biopharmaceutical company Intercept Pharmaceuticals (NasdaqGS:ICPT) said on Tuesday that it has completed the public offering of 1,000,000 shares of its common stock.
ICPT: 209.12 (+7.12)
Intercept Pharma completes equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:22PM CST
ICPT: 209.12 (+7.12)
Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
GlobeNewswire - Tue Feb 10, 3:08PM CST
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced the completion of its previously announced underwritten public offering of 1,000,000 shares of its common stock. In addition, the underwriters have exercised in full their option to purchase an additional 150,000 shares of common stock.
ICPT: 209.12 (+7.12)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
Does This Small Biotech Have the Making of a Blockbuster?
Motley Fool Staff - Motley Fool - Sat Feb 07, 8:59AM CST
Source: Flickr user Stockmonkeys.com. When it comes to developing billion-dollar blockbuster drugs, the odds are stacked against biotech companies. About 90% of drugs that enter clinical trials fail, and of those that do eventually get approved,...
OPHT: 51.11 (+0.12), ICPT: 209.12 (+7.12), ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Intercept Pharmaceuticals (ICPT) Jumps: Stock Adds 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:25AM CST
Intercept Pharmaceuticals (ICPT) was a big mover last session, with shares rising roughly 10% on the day.
ICPT: 209.12 (+7.12), AFFX: 11.45 (+0.02)
Why Intercept Pharmaceuticals Inc. Shares Shot Higher By 29% in January
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 05, 10:04AM CST
ICPT data by YCharts What: Shares of Intercept Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat liver and intestinal diseases, shot higher by 29% in January per S&P Capital IQ after...
ICPT: 209.12 (+7.12)
Intercept Pharmaceuticals prices public offering at USD176.00 per share
M2 - Thu Feb 05, 5:45AM CST
Biopharmaceutical company Intercept Pharmaceuticals (NasdaqGS:ICPT) said on Wednesday that it has priced its public offering of 1,000,000 shares of its common stock at USD176.00 per share.
ICPT: 209.12 (+7.12)
Intercept Pharmaceuticals Announces Pricing of Public Offering
GlobeNewswire - Wed Feb 04, 6:34PM CST
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $176.00 per share. In addition, Intercept has granted the underwriters a 30-day option to purchase up to an additional 150,000 shares of common stock.
ICPT: 209.12 (+7.12)
Intercept Pharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 9:04PM CST
ICPT: 209.12 (+7.12)
Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Feb 03, 3:18PM CST
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced that it has commenced an underwritten public offering of 800,000 shares of its common stock. All of the shares in the offering are to be sold by Intercept.
ICPT: 209.12 (+7.12)
Intercept Pharmaceuticals (ICPT) Marked As A Dead Cat Bounce Stock
at The Street - Tue Feb 03, 1:17PM CST
Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a "dead cat bounce" (down big yesterday but up big today) candidate
ICPT: 209.12 (+7.12)
Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 03, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ARLP: 39.29 (+1.84), HTBX: 5.83 (+0.22), EVOK: 5.41 (-0.10), ADXS: 7.18 (+0.06), RCII: 30.49 (+0.92), SCYX: 9.48 (+0.07), SONS: 17.69 (-0.01), SSYS: 67.16 (-0.34), ICPT: 209.12 (+7.12), VBLT: 14.11 (+0.24), LMNX: 15.45 (+0.02), OMER: 20.63 (+0.13)
Critical Alerts For Zynga, Intercept Pharmaceuticals, Biogen, Nabors Industries and CyberArk Software Released By InvestorsObserver
PR Newswire - Mon Feb 02, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ZNGA, ICPT, BIIB, NBR and CYBR.
BIIB: 391.66 (-0.45), CYBR: 52.52 (+6.83), NBR: 12.73 (+0.52), ICPT: 209.12 (+7.12), ZNGA: 2.24 (-0.42)
Quarterly Results Review & Outlook: Complementary Reports on Costco, Chevron, ImmunoGen, MasterCard, and Intercept
PR Newswire - Mon Feb 02, 6:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Costco (NASDAQ: COST), Chevron (NYSE: CVX), ImmunoGen (NASDAQ: IMGN), MasterCard (NYSE: MA), and Intercept (NASDAQ: ICPT). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
IMGN: 7.19 (unch), ICPT: 209.12 (+7.12), COST: 147.10 (-0.66), CVX: 112.78 (+1.92), MA: 87.14 (-0.38)
Intercept Pharmaceuticals wins US FDA's "breakthrough therapy designation" for investigational product obeticholic acid for NASH with liver fibrosis
M2 - Mon Feb 02, 5:20AM CST
Biopharmaceutical company Intercept Pharmaceuticals (NasdaqGS:ICPT) revealed on Friday that it has received "breakthrough therapy designation" for its investigational product obeticholic acid (OCA) from the US Food and Drug Administration (FDA) for treating patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis.
ICPT: 209.12 (+7.12)
Intercept Pharmaceuticals' OCA Now Breakthrough Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 3:54PM CST
Intercept Pharmaceuticals, Inc.'s (ICPT) obeticholic acid (OCA) received Breakthrough Therapy designation from the FDA for nonalcoholic steatohepatitis (NASH).
MNK: 115.01 (+2.51), ICPT: 209.12 (+7.12), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Primary Sclerosing Cholangitis Therapeutic Pipeline Review H1 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Fri Jan 30, 3:30PM CST
The report "Primary Sclerosing Cholangitis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Primary Sclerosing Cholangitis. Primary sclerosing cholangitis is a liver disease in which the bile ducts gradually decrease in size due to swelling and scarring. Different treatments are available to control symptoms that may develop and also to manage any complications which may occur. Many people with primary sclerosing cholangitis do not get symptoms, especially in the early stages of the disease. The most common symptoms are fatigue, pruritus, jaundice and yellowing of the skin and eyes. The symptoms of this disease can be treated with antibiotics, vitamins and medications to control itching, improve bile flow etc. Complete Report is Available at http://www.rnrmarketresearch.com/primary-scle...eport.html.
GILD: 101.90 (+1.10), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
